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Abstract: Almotriptan is an orally administered, highly selective serotonin 5-HT(1B/1D) 
receptor agonist that is effective in the acute treatment of moderate to severe migraine attacks. 
Since its introduction on to the market in 2001, several studies involving a large number of 
migraine patients have conﬁ  rmed its efﬁ  cacy and tolerability proﬁ  le. Almotriptan, was found 
to be among the best-responding triptans in terms of pain relief and pain-free rate at 2 h. It has 
been reported that almotriptan has the best sustained pain-free (SPF) rate and the lowest adverse 
events (AEs) rate of all the triptans. When these clinical characteristics were combined to form 
the composite endpoint SPF and no AEs (SNAE), almotriptan emerged as the triptan with the 
best efﬁ  cacy and tolerability proﬁ  le. It also showed a good efﬁ  cacy proﬁ  le during the early 
treatment (within 1 h of onset) of migraine attacks characterized by moderate pain intensity. 
On the basis of these ﬁ  ndings, almotriptan may be considered a therapeutic option for the acute 
treatment of migraine attacks.
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Introduction
Migraine is a very common chronic and sometimes progressive (Lipton and Pan 2004) 
neurological disorder, characterized by recurrent attacks of pulsating headache with or 
without aura, aggravated by physical activity and associated with vegetative symptoms 
(eg, sensitivity to light and noise, nausea, and vomiting) (IHS 2004). It affects women 
three times more frequently than men, and the majority of sufferers are aged between 
25 and 55 years, which are usually an individual’s most productive and socially active 
years (Lipton and Bigal 2005).
In a World Health Organization (WHO) report in 2000 (Mathers et al 2002), 
migraine was ranked 19 among disorders causing years lived with a disability for 
both sexes (and 9 when considering only women), and the level of disability during 
a severe migraine attack is considered to be on a par with that associated with active 
psychosis, tetraplegia and dementia.
The estimated mean prevalence of migraine in Europe is 16.6% in women and 
7.5% in men (Stovner et al 2006); in the US, the corresponding ﬁ  gures are 18.2% 
and 6.5% (Lipton et al 2001). Because of its peculiar clinical and epidemiological 
features, migraine places a signiﬁ  cant economic burden on society, estimated (in 
terms of reduced productivity and missed workdays) to amount, annually, to €27 
billion in the European Community (Andlin-Sobocki et al 2005) and $13 billion in 
the US (Hu et al 1999). The pathophysiology of migraine is linked, essentially, to 
a genetic component and to peripheral activation of the ophthalmic branch of the 
trigeminal nerve, probably caused by neurogenic plasma protein extravasation and 
neuropeptide release (so-called neurogenic inﬂ  ammation) (Markowitz et al 1987; 
Moskowitz 1990), as well as to activation of second order neurons on the superﬁ  cial 
lamina of the trigeminal nucleus caudalis (Goadsby and Zagami 1991), as hypoth-
esized after animal studies.Neuropsychiatric Disease and Treatment 2007:3(6) 800
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In both neurogenic inﬂ  ammation and central sensiti-
zation of the trigeminal nerve it has been demonstrated, 
through the activity of different subtypes of serotonin recep-
tor, such as 5-HT1B, which is responsible for vasoconstric-
tion and inhibition of neurogenic inﬂ  ammation (Buzzi and 
Moskowitz 1990; Yu et al 1996), and 5-HT1D, responsible 
for inhibition of trigeminal neuronal activation (Storer and 
Goadsby 1997), that serotoninergic transmission plays a 
pivotal role. This led to the synthesis and development of 
5-HT1B/1D receptor agonists, the triptans, for the treatment 
of migraine attacks.
According to American and European practice guidelines 
(Silberstein 2000; EFNS task force 2006), and as conﬁ  rmed 
by a survey of acute migraine sufferers (Lipton et al 2002), 
the outcome measures of acute migraine treatment consid-
ered most important are rapid onset of efﬁ  cacy, complete 
pain relief without recurrence, reduced need for rescue 
medication, and no adverse events (AEs). More recently, in 
order to represent more accurately what migraine patients 
want from their acute migraine therapy, composite end-
points encompassing the measures able to predict patient 
satisfaction (such as pain-free state, use of rescue medica-
tion, AEs) have been developed and introduced (Sandrini 
et al 2005).
In recent years the triptans have become the recom-
mended drugs for the acute treatment of moderate and severe 
migraine attacks, and in patients who failed to respond to 
non-speciﬁ  c agents (Silberstein 2000), on account of their 
very favorable efﬁ  cacy and tolerability proﬁ  le.
Seven triptans are currently available for the treatment 
of acute migraine (almotriptan, eletriptan, frovatriptan, 
naratriptan, rizatriptan, sumatriptan and zolmitriptan) and 
they have been found to show a signiﬁ  cant variability in 
terms of their efﬁ  cacy and tolerability.
Almotriptan, which several studies have shown to be 
effective and tolerable, represent a ﬁ  rst-line treatment for 
acute migraine attacks.
Pharmacology
Binding and in vitro studies have shown that almotrip-
tan (3-[2-dimethylamino ethyl]-5-(pyrrolidin-1-ylsulfonyl-
methyl)-1H-indole) is a potent and selective 5-HT(1B/1D) 
receptor agonist. It has high afﬁ  nity (in the low nM range) 
and high selectivity for serotonin 5-HT human cloned recep-
tor 1B/1D and for those in animal tissues (Bou et al 2000), 
but lower afﬁ  nity for all the other serotoninergic receptors. 
Its afﬁ  nity for 5-HT1A receptors is more than 60-fold lower 
than its afﬁ  nity for 5-HT1B/1D receptors, and about 40-fold 
lower than its afﬁ  nity for 5-HT7 receptors. Similarly, sig-
niﬁ  cant afﬁ  nity was found for 5-HT6 receptors, although the 
clinical potential of 5-HT6 and 5-HT7 receptor ligands is still 
unknown (Bou et al 2000). Almotriptan has been studied in 
human cloned transfected 5-HT1F receptors, for which it also 
shows signiﬁ  cant afﬁ  nity, about 20 nM (Bou et al 2000).
As regards its action, it has been postulated that almo-
triptan, like other triptans, induces both vasoconstriction, 
by acting on the 5-HT1B receptor subtype, and inhibition of 
nociceptive transmission, via 5-HT1D receptor interaction 
(Bou et al 2001; Hoskin et al 2004).
When the contractile effect of almotriptan and sumat-
riptan was studied in preparations of isolated vessels from 
the human brain (meningeal, temporal, basilar and internal 
carotid arteries), coronary arteries and other vascular beds, 
almotriptan showed a superior potency and efﬁ  cacy in con-
tracting the meningeal artery compared to sumatriptan, and 
a similar efﬁ  cacy to sumatriptan on cranial vessels that are 
not directly involved in migraine pathophysiology and on 
extracranial vessels. On the contrary, almotriptan dislayed 
a lower contractile effect compared to sumatriptan on 
vessels (ie, coronary arteries) suggested to be related to AEs 
associated with the triptans (Bou et al 2001). Almotriptan 
(0.3 mg/kg) inhibits the extravasation of plasma from dural 
vessels following trigeminal ganglion stimulation, exerting 
an action similar to that of sumatriptan (1 mg/kg) (Gras et al 
2000). Inhibition of nociceptive transmission by activating 
the 5-HT1D receptors in peripheral trigeminal sensory nerve 
terminals in the meninges and central terminal in brain stem 
sensory nuclei, as demonstrated for other triptans (Hoskin 
et al 2004), can be hypothesized for almotriptan, too, and 
could explain not only its efﬁ  cacy on pain transmission 
at brainstem level, but also its effect on the associated 
symptoms, including nausea and vomiting.
The bioavailability of almotriptan after oral administra-
tion is approximately 70% (Jansat et al 2002), similar to that 
of naratriptan, but signiﬁ  cantly higher than the range reported 
for the other triptans (14%–50%) (Jhee et al 2001). Absorp-
tion is rapid, maximal plasma concentration is achieved 
between 1.5 and 4 h after dose administration; however, after 
1 h the plasma concentration is 68% of the Cmax (Fleishaker, 
Ryan, Carel et al 2001).
The mean half-life ranges between 3 and 5 h (McEnroe 
and Fleishaker 2005), in line with other triptans but signiﬁ  -
cantly lower than the 25 h half-life of frovatriptan (Tfelt-
Hansen et al 2000). Almotriptan is largely distributed in 
body ﬂ  uids with a volume of distribution, after intravenous 
administration, of 1951; as with other triptans, its protein Neuropsychiatric Disease and Treatment 2007:3(6) 801
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binding does not reach 40% (Gras et al 2002). Almotriptan 
is eliminated, mainly in urine (75%) but also in feces (12%), 
within 1 week of administration, although more than half of 
the dose administered is eliminated within the ﬁ  rst 6 hours 
(McEnroe and Fleishaker 2005). Almotriptan is metabolized 
in vivo primarily via oxidation by monoamine oxidase-A 
and then by cytochrome P450 (CYP) (3A4 and 2D6 iso-
enzymes) and ﬂ  avin monooxygenase in three compounds: 
indolacetic acid and its glucuronide conjugate and the 
oxidized pyrrolidine product (Jansat et al 2002). Around 
30%–40% of the dose is excreted in the urine unchanged, 
27% is metabolized by monoamine oxidase-A, and a small 
percentage is metabolized by CYP. Since urinary excretion is 
the primary route of elimination, renal function is the factor 
that most conditions almotriptan clearance, followed by 
enzymatic metabolism. On this basis, some authors recom-
mend that the dosage be limited to 1 tablet/24 h in migraine 
patients with severe renal disease (Dodick 2003). Hepatic 
impairment, even when severe, does not appear to affect 
the pharmacokinetic parameters much more than impaired 
renal function does, and in this situation, too, 1 tablet/24 h is 
recommended as the maximum daily intake (McEnroe and 
Fleishaker 2005). The fasted or fed condition has not been 
found to modify signiﬁ  cantly the bioavailability proﬁ  le or the 
therapeutic effect of almotriptan (Jansat et al 2006).
Almotriptan has been tested for its potential phar-
macokinetic interaction with several drugs, including 
MAO-A inhibitors (Fleishaker, Ryan, Jansat et al 2001), 
SSRIs (Fleishaker, Ryan, Carel et al 2001), β-adrenergic 
(Fleishaker, Sisson et al 2001) and calcium channel blocking 
agents (Fleishaker et al 2000), and ketokonazole (Fleishaker 
et al 2003), and even though some pharmacokinetic interac-
tion was shown, including an increased plasma concentration 
of almotriptan, the authors did not ﬁ  nd a clinically signiﬁ  -
cant proﬁ  le. Consequently, no dose adjustment is necessary 
when almotriptan is taken together with these drugs. On the 
contrary, the recommendation to wait for at least 24 h before 
taking a triptan following administration of any ergotamine-
containing preparation is still valid.
The pharmacokinetic characteristics of almotriptan are 
given in Table 1.
Clinical efﬁ  cacy
The clinical efﬁ  cacy and tolerability of almotriptan has been 
tested in two controlled, double-blind, randomized clinical tri-
als against placebo (Pascual et al 2000; Dahlof et al 2001) and 
in two trials (Spierings et al 2001; Dowson et al 2002) that also 
included sumatriptan. Together, these four trials included 2500 
patients who met the International Headache Society (IHS) 
criteria for moderate-to-severe acute episodic migraine.
In the ﬁ  rst trial (Pascual et al 2000), the 722 patients 
who completed the study received a single dose of pla-
cebo, almotriptan 6.25 mg, or almotriptan 12.5 mg during 
three consecutive migraine attacks of moderate or severe 
intensity.
The primary endpoint was the number of migraine attacks 
out of the three, in which there was pain relief (pain reduced 
from moderate or severe to mild or no pain) at 2 h after intake. 
A consistent response was achieved across and within patients 
for almotriptan, 6.25 or 12.5 mg, compared with placebo (pain 
relief within 2 h in at least two out of three attacks in 64% and 
75% vs 36% of patients, respectively). Similarly, pain relief 
at 2 h was found to be signiﬁ  cantly higher (p   0.001) after 
treatment with almotriptan, 6.25 (60%) or 12.5 mg (70%), 
compared with placebo (38%) (Table 2). The number and 
percentage of attacks, out of the three, that were pain-free 
at 2 h, without use of rescue medication, were signiﬁ  cantly 
higher (p   0.001) after almotriptan, 6.25 (29.9%) and 12.5 mg 
(38.8%), than after placebo (15.5%) (Table 2). In terms of onset 
of action, almotriptan 6.25 mg (30.1%) and almotriptan 12.5 mg 
(34.5%) both showed a signiﬁ  cant (p   0.001) percentage 
increase in the number of attacks in which relief was obtained 
after 1 h compared with placebo (21.6%), and almotriptan 
12.5 mg (12.5%) was also signiﬁ  cantly (p   0.01) more 
efﬁ  cacious than both almotriptan 6.25 mg (7.3%) and placebo 
(5.7%) in producing pain-free state 1 h after treatment. Three of 
the migraine-related symptoms considered (phonophobia, pho-
tophobia and vomiting) improved signiﬁ  cantly (all p   0.01) 
following almotriptan 12.5 mg as opposed to placebo intake. 
No signiﬁ  cant differences in terms of relapses were found 
when almotriptan 12.5 mg (30.1%) and 6.25 mg (28.7%) were 
compared with placebo (23.3%). Nearly a quarter (23.1%) of 
patients experienced an AE. The AE rate decreased from the 
Table 1 Pharmacokinetic characteristics of almotriptan
Treatment characteristics  Almotriptan
5-HT receptor afﬁ  nity  1B/1D
Tmax (h)  1.5–2.0
Half-life (h)   3–5
Bioavailability (%)   70
Volume of distribution (l)  195 
Metabolism   MAO-A
 CYP450
Elimination Renal  (75%)
Elimination renal inactive (%)  50
Lipophilicity low
CNS side effects (%)   –1.5Neuropsychiatric Disease and Treatment 2007:3(6) 802
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ﬁ  rst to the third attack and there were no signiﬁ  cant differences 
between the groups in the percentages of AEs.
A dose-finding, placebo-controlled, double-blind, 
parallel-group, phase II study (Dahlof et al 2001) investigated 
742 migraineurs who were randomized to a single dose of 
placebo or oral almotriptan (2, 6.25, 12.5, or 25 mg) and 
instructed to treat when pain was moderate or severe.
The number of patients with headache response at 2 h, 
deﬁ  ned as a decrease from severe or moderate pain at baseline 
to mild or no pain 2 h after study treatment without the use 
of escape medication, was the primary endpoint. The patients 
with headache response at 2 h were 32.5% after placebo, and 
30.0%, 56.3%, 58.5%, and 66.5% after almotriptan 2, 6.25, 
12.5, and 25 mg respectively (Table 2) showing a signiﬁ  cant 
dose dependent increase (p   0.0001). The doses from 6.25 to 
25 mg demonstrated greater efﬁ  cacy compared with placebo 
(p   0.001), without signiﬁ  cant differences emerging in 
response at 2 hours between the doses in this range.
The percentages of patients who were completely pain-
free within 2 h of almotriptan ingestion were 37.8% and 
45.3% in the 12.5-mg and 25-mg treatment groups, compared 
with 11.3% in the placebo group. Moreover, all the doses 
of almotriptan showed signiﬁ  cantly higher percentages of 
pain-free patients at 1, 1.5, and 2 h compared with placebo. 
The percentages of associated symptoms (nausea, vomiting, 
phonophobia, and photophobia) tended to improve in a 
dose-dependent manner (all p   0.001), even though the 
majority of patients reported these symptoms as unchanged. 
AEs were experienced by 18.7% of the randomized patients, 
and the incidence and intensity of these AEs were dose-
dependent, reaching signiﬁ  cance at the 25 mg dose (which 
was also the dose at which more patients experienced AEs 
whose severity they considered moderate). On contrary, 
the incidence of AEs at all other doses of almotriptan was 
similar to that found in the placebo group. On the basis of 
these efﬁ  cacy and tolerability data the authors suggest that 
12.5 mg is the optimal dose of almotriptan.
In the randomized, single-dose, double-blind, parallel-
group, placebo-controlled, multicenter clinical study by 
Dowson et al (2002), almotriptan, 12.5 and 25 mg, was 
compared with sumatriptan 100 mg. A total of 668 patients 
treated one migraine attack of moderate or severe intensity 
with the study medication. Pain relief at 2 h after treatment 
(deﬁ  ned as improvement from severe or moderate pain to 
mild or no pain at 2 h after treatment) was the primary endpoint. 
The response rates for moderate or severe pain were 56.8% 
after almotriptan 12.5 mg, 56.5% after almotriptan 25 mg, 
and 63.7% after sumatriptan, all three active treatments thus 
giving signiﬁ  cantly better results than the placebo, which 
recorded a response rate of 42.4%. Considering pain relief at 
2 h stratiﬁ  ed by intensity of the attack (moderate or severe), 
almotriptan (both doses) and sumatriptan both showed a 
Table 2 Data from clinical trials of almotriptan
  No. of patients  Pain relief 2 h (%)  Pain-free 2 h (%)
Pascual et al 2000
Placebo 176  38.4  15.5
Almotriptan 6.25 mg  360  59.9*  29.9*
Almotriptan 12.5 mg  373  70.3*  38.8*
Dahlof et al 2001    
Placebo   80  32.5  11.3
Almotriptan 2 mg  170  30  17.1
Almotriptan 6.25 mg  167  56.3*  30.0*
Almotriptan 12.5 mg  164  58.5*  37.8*
Almotriptan 25 mg  161  66.5*  45.3*
   Stratiﬁ  ed for baseline pain level
Dowson et al 2002   moderate  severe  moderate  severe
Placebo   99  46.3  34.4  16.4  12.5
Almotriptan 12.5 mg  184  72.0  41.1  38.7  16.7
Almotriptan 25 mg  191  66.7  44.2  46.7  19.8
Sumatriptan 100 mg  194  73.9  50.0  36.9  29.3
Spierings et al 2001    
Almotriptan 12.5 mg  591    58.0    17.9
Sumatriptan 50 mg  582    57.3    24.6**
*statistically signiﬁ  cant difference (p   0.001) when compared with placebo.
**statistically signiﬁ  cant difference (p   0.05) when compared with almotriptan.Neuropsychiatric Disease and Treatment 2007:3(6) 803
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signiﬁ  cantly better response than placebo, with sumatriptan 
100 mg giving better results than almotriptan (Table 2).
When the secondary endpoint “pain-free at 1 h and 2 h” 
was stratiﬁ  ed by intensity of the pain (moderate or severe), 
the authors found that, among the patients reporting moderate 
pain, the rates of pain-free responses at 2 h were consider-
ably higher in both the almotriptan (38.7% for the 12.5 mg; 
46.7% for the 25-mg dose) and the sumatriptan (36.9%) 
groups (almotriptan 25 mg giving the best results) than in the 
placebo group (16.4%); the pattern was similar in the patients 
reporting severe pain (albeit based on less evidence and with 
the best response found in the sumatriptan group) (Table 2). 
On the contrary, when considering only the pain-free at 1 h 
endpoint, the tested drugs showed a better response than the 
placebo (almotriptan 25 mg giving the best results) only in the 
patients reporting moderate pain, while in those with severe 
pain the drugs and placebo gave similar results.
The recurrence rate after 24 h in patients treating severe 
pain was signiﬁ  cantly lower after treatment with almotriptan 
12.5 mg (8.8%) and 25 mg (16.2%) than after treatment with 
either sumatriptan (28.9%) or placebo (27.3%). While no dif-
ferences were found in the recurrence rate between the groups 
when moderate pain was treated (almotriptan 12.5 mg = 
22.7%, almotriptan 25 mg = 14.9%, sumatriptan = 22.4%, 
placebo = 16.7%), all three active treatments reduced the 
incidence of associated symptoms compared with placebo, 
and also showed a lower rate of recourse to rescue medication 
(almotriptan 12.5 mg = 38.6%; almotriptan 25 mg = 38.2%; 
sumatriptan = 32.4%) than placebo (55.5%). This study 
reported a very low rate of AEs, both for almotriptan and 
for sumatriptan.
In a large double-blind, placebo-controlled study 
(Spierings et al 2001), the efﬁ  cacy, safety and tolerability 
proﬁ  le of almotriptan 12.5 mg was compared with that of 
sumatriptan 50 mg, enrolling 1173 subjects who treated mod-
erate or severe migraine headache. The primary endpoints 
were pain relief (deﬁ  ned as a decrease in pain intensity from 
moderate or severe at baseline to mild or no pain at 2 h after 
treatment) and pain-free state (deﬁ  ned as a decrease in pain 
intensity from moderate or severe at baseline to no pain at 
2 h after treatment) at 2 h. With regard to the ﬁ  rst of these, 
both almotriptan and sumatriptan showed a similar rate 
(58.0% and 57.3% respectively), whereas sumatriptan 50 mg 
(24.6%) proved signiﬁ  cantly (p = 0.05) more efﬁ  cacious than 
almotriptan (17.9%) in producing headache freedom at 2 h 
(Table 2). No signiﬁ  cant differences emerged between the 
two study drugs when the two endpoints were evaluated at 
0.5 and at 1 h. Similarly, no differences were found between 
the capacity of almotriptan 12.5 and sumatriptan 50 mg to 
reduce migraine-associated symptoms. Rescue medication 
was used by 36.7% of the almotriptan-treated and by 33.2% 
of the sumatriptan-treated patients. The recurrence rate 
within 24 h of a moderate or severe headache was 27.4% 
after treatment with almotriptan and 24.0% after treatment 
with sumatriptan, a difference that did not reach statistical 
signiﬁ  cance. Both drugs showed a good tolerability proﬁ  le 
and no serious AEs were reported.
A recent meta-analysis (Dahlöf et al 2006) of 4 randomized, 
placebo-controlled, double-blind clinical trials has produced 
further signiﬁ  cant clinical data in favor of almotriptan. On the 
basis of this analysis of more than 1900 doses of almotriptan 
and almost 400 of placebo, it emerged, as early as 30 min after 
dosing, that almotriptan 12.5 mg was signiﬁ  cantly more effec-
tive than placebo in producing pain relief (14.9% vs 8.2%; p   
0.05) and pain-free state (2.5% vs 0.7%; p   0.05).
The composite endpoint
In a survey of 1660 migraineurs experiencing severe head-
ache or migraine, pain relief and speed of onset were impor-
tant treatment attributes for more than 75% of sufferers, and 
the absence of AEs was important to over 40% (Gallagher 
and Kunkel 2003). It was estimated that AEs caused more 
than 70% of the patients to delay or avoid taking medication, 
which had signiﬁ  cant negative repercussions on headache 
intensity and duration and social functioning (Gallagher 
and Kunkel 2003). For migraineurs, the most important 
attributes of acute treatments are complete pain relief, lack 
of recurrence, rapid onset of action, and absence of AEs. 
A randomized controlled trial of rizatriptan showed that 
patients who experience complete pain relief and are able 
to function at their normal levels within 2 h and experience 
no headache recurrence have the highest migraine-speciﬁ  c 
quality of life scores (Santanello et al 2002). In the light of 
these ﬁ  ndings, and also in order to better reﬂ  ect what patients 
want from their migraine treatment, a composite clinical 
endpoint has been developed that combines the sustained 
pain-free (SPF) rate, deﬁ  ned as pain-free at 2 h after medica-
tion administration with no recurrence of moderate-to-severe 
headache and no use of rescue medication from 2 to 24 h 
post-dose (Tfelt-Hansen et al 2000), with the outcome no 
AEs (SNAE); this composite endpoint, by including toler-
ability (Dodick et al 2007), another crucial factor in migraine 
treatment, is thus an evolution of the SPF.
The SPF rate was considered in a pooled analysis (Dodick 
2002) of three randomized, double-blind, placebo-controlled 
trials evaluating the efﬁ  cacy of almotriptan. Two studies Neuropsychiatric Disease and Treatment 2007:3(6) 804
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compared almotriptan, 6.25 mg and 12.5 mg, with placebo, 
and the third almotriptan 12.5 mg and sumatriptan 100 mg.
In all three studies, both the almotriptan (6.25 mg and 
12.5 mg) and sumatriptan gave signiﬁ  cantly better (p   0.05) 
SPF rates than placebo. Taking into account the intensity of 
the baseline pain (moderate or severe pain), among patients 
with moderate pain almotriptan, 6.25 mg showed a signiﬁ  -
cantly better SPF with respect to placebo in one study (25.5% 
vs 10.2%, p   0.032) (Table 3), while almotriptan 12.5 mg 
gave a signiﬁ  cantly higher SPF rate than placebo in both the 
studies (31.3% vs 10.2%, p   0.004 and 32.0% vs 16.1%, 
p   0.002) (Table 3). Among patients with severe pain, 
almotriptan 6.25 mg showed a signiﬁ  cantly better results than 
placebo in one study (21.5% vs 3.1%, p   0.005), while, also 
in this case, almotriptan 12.5 mg resulted signiﬁ  cantly better 
in both the studies (17.3% vs 3.2%, p   0.032 and 20.9%, 
p   0.001) (Table 3).
In the trial that also considered sumatriptan, the propor-
tion of patients achieving SPF was similar between almo-
triptan 12.5 mg and sumatriptan 100 mg and signiﬁ  cantly 
higher than that in placebo group. The SPF rates produced 
by almotriptan 12.5 mg (33.3%) and sumatriptan 100 mg 
(31.5%) in patients with moderate pain at baseline were 
similar and signiﬁ  cantly higher than those in the placebo 
group (p   0.05). In patients treating severe pain, sumatriptan 
100 mg gave a signiﬁ  cantly higher SPF rate than placebo, 
whereas no significant differences were noted between 
almotriptan 12.5 mg and placebo (Table 3).
A very interesting clinical proﬁ  le of almotriptan 12.5mg 
emerged from a recent analysis (Dodick et al 2007) of the 
data derived from a large meta-analysis of 53 clinical trials 
of triptan efﬁ  cacy and tolerability that evaluated more than 
24000 patients (Ferrari et al 2002). The relationship between 
SPF and AEs was investigated in order to consider the ratio-
nale for using the SNAE endpoint in clinical trials. The results 
showed that higher SPF rates were related to higher AE rates, 
except after administration of almotriptan 12.5 mg, which 
showed the lowest AE rate (14.2%; approximately 30% lower 
than expected) and the highest SPF rate (25.9%), coupled 
with the highest SNAE rate (22.2%; range 11.7%–25.9%), 
of the six triptans evaluated (Figure 1).
Early treatment with almotriptan
A growing body of evidence supports the increased efﬁ  cacy 
of migraine attack treatment with symptomatic drugs over 
the conventional approach (until now widely employed in 
clinical trials), which is to treat when the pain is moderate 
or severe. This is especially true in the case of the triptans, 
where early treatment is associated with higher pain-free 
rates, together with reductions in rescue medication use and 
recurrence rates (Lainez 2004).
Almotriptan has been evaluated in several retrospec-
tive analyses which set out to address the beneﬁ  ts of early 
intervention, during the mild phase of the attack. In a post-
hoc analysis (Pascual and 2002) of a trial involving 762 
migraineurs who treated 6 attacks, 3 during mild pain and 
3 during moderate or severe pain, the pain-free rate at both 
1 h and 2 h post-dose was signiﬁ  cantly greater in the patients 
who treated their attacks when the pain was mild (47% and 
84%, respectively) as opposed to moderate or severe (14% 
and 53% respectively). Also, the consistency of the pain 
relief (pain-free in at least two out of three attacks) at both 
1 h and 2 h was signiﬁ  cantly increased in the patients who 
treated mild pain (45% and 88% respectively) compared to 
patients who treated moderate or severe pain (14% and 56% 
respectively). Similarly, both the recurrence rate and the need 
for rescue medication were signiﬁ  cantly lower in those who 
treated mild pain (28% and 8% respectively) as opposed to 
moderate or severe pain (33% and 13% respectively).
Another post-hoc analysis (Mathew 2003) was based on a 
multicenter, open-label, long-term trial (Mathew et al 2002) 
involving 582 patients who treated 10645 migraine attacks 
with almotriptan 12.5 mg. Treatment when pain was mild gave 
signiﬁ  cantly higher pain-free rates at both 1 h (p   0.001) and 
2 h (p   0.001) (35.3% and 76.9% respectively) compared 
to treatment when pain was moderate or severe (7.5% and 
43.9% respectively). The recurrence rate and use of rescue 
medication were also signiﬁ  cantly lower (both p   0.001) 
in the patients who treated their attacks when the pain was 
mild (12.9% and 9.4% respectively) as opposed to moderate 
or severe (25.0% and 17.2% respectively). The SPF rate in 
Table 3 Patients with sustained pain-free according to baseline 
pain severity as considered in a pooled analysis of three placebo-
controlled trials by Dodick (2002)
  Moderate pain (%)  Severe pain (%)
Placebo 10.2  3.2
Almotriptan 6.25 mg  25.5*  16.2
Almotriptan 12.5 mg  31.3*  17.3*
Placebo   16.1  3.1
Almotriptan 6.25 mg  25.6  21.5*
Almotriptan 12.5 mg  32.0*  20.9*
Placebo   15.0  6.0
Almotriptan 6.25 mg  33.0*  15.0
Sumatriptan 100 mg  31.5*  24.0*
*statistically signiﬁ  cant difference (p   0.05) when compared with placebo.Neuropsychiatric Disease and Treatment 2007:3(6) 805
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patients who treated mild pain (66.6%) was nearly twice that 
recorded in patients who treated moderate or severe pain 
(36.6%) (p   0.001).
A further retrospective analysis (Dowson et al 2004) 
evaluated 253 subjects from a cohort of 475 migraineurs who 
took part in a double-blind, randomized, placebo-controlled 
trail comparing almotriptan 12.5 mg and sumatriptan 100 mg. 
The pain-free rates at 2 h were 37.9% for almotriptan 12.5 mg 
(p = 0.016 vs placebo), 35.7% for sumatriptan 100 mg (p = 
0.028 versus placebo), and 18.9% for placebo. Only almo-
triptan gave a signiﬁ  cantly higher SPF rate (34.7%) than 
placebo (p = 0.022 versus placebo); sumatriptan gave an 
SPF rate of 29.6%, and placebo one of 17.0%. In a recent 
multicenter, double-blind, placebo-controlled, parallel-group 
clinical trial (Mathew et al 2007), 378 migraine patients 
were randomized to treat three migraine attacks with either 
almotriptan 12.5 mg or placebo. Patients were instructed 
to take the study medication within 1 hour of onset of the 
headache pain. Compared with the placebo group, the 162 
patients treated with almotriptan showed signiﬁ  cant dif-
ferences in pain-free (almotriptan 16.7%; placebo 8.4% p 
= 0.026) and pain relief rates (almotriptan 54.3%; placebo 
41.1% p = 0 .019) within 1 h post dose. Similarly, highly 
signiﬁ  cant differences were found in the almotriptan-treated 
versus the placebo group in 2-h pain-free (37.0% vs 23.9%, 
p = 0.010), 2-h pain relief (72.3% vs 48.4%, p   0.001) and 
SPF (24.7% vs 16.1%, p = 0.040) rates.
Safety and tolerability
In many studies investigating the AEs typically associated 
with the triptans, almotriptan was found to show a good safety 
proﬁ  le, comparable with that of placebo.
In a pooled analysis (Dodick 2001), three phase 1 dose-
ﬁ  nding and pharmacokinetic studies, in healthy subjects, 
evaluated the safety and tolerability of almotriptan after 
single doses ranging from 2 to 200 mg. In one of these, single 
doses of almotriptan, 5 to 200 mg, were administered to 
22 healthy subjects, 70% reported an overall of 49 AEs (7 in 
the placebo group), particularly at the higher doses. The most 
frequent AEs were headache and drowsiness, also present 
in the placebo group, while nausea, raised blood pressure, 
panparesthesia, lightheadedness, heaviness in the chest and 
muscular fatigue were considered to be related to almotriptan. 
In another two open-label, single-dose, pharmacokinetic 
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study, a total of 48 healthy subjects received almotriptan 
at 12.5 mg and 25 mg. The most common AEs were head-
ache and fatigue, and there were no life-threatening events. 
A slight, transient (6 h) increase in blood pressure was 
observed after dosing.
In the same pooled analysis (Dodick 2001), the safety 
and tolerability of almotriptan was evaluated in phase II 
and III studies involving about 2500 patients and more than 
15000 migraine attacks. In these studies, AEs occurred with 
an incidence of 3%–5%. The most common symptoms were 
dizziness, nausea and vomiting, headache, fatigue, pares-
thesia and drowsiness. Interestingly, the incidence of chest 
symptoms was only 0.2%. In a phase II trial, almotriptan 
in doses ranging from 2 to 150 mg was administered to 
169 migraineurs: 28 (16.6%) experienced AEs (about 50% 
in the 150-mg group), 7 of which were probably related to 
the almotriptan, and there were no serious AEs. In another 
phase II trial, 139 (18.7%) out of 742 patients reported AEs, 
of which a signiﬁ  cantly greater number were reported in the 
25 mg group, the most common being nausea, dry mouth, 
paresthesia, dizziness and diarrhea. In a phase III, double-
blind, placebo-controlled study, 910 patients received a single 
6.25 mg or 12.5 mg dose of almotriptan or placebo, while 722 
treated three migraine attacks with the study medication. Two 
hundred and ten patients (23.1%) experienced AEs, without 
statistically signiﬁ  cant differences in incidence emerging 
between the placebo (21.6%) and the treatment groups 
(21.1%, 6.25 mg; 25.7%, 12.5 mg). The most frequent AEs, 
occurring in no more than 3% of patients, included dizziness, 
vomiting, paresthesia and nausea.
The good tolerability proﬁ  le of almotriptan has also been 
conﬁ  rmed in large clinical studies in which it was compared 
with sumatriptan.
In a randomized, single-dose, double-blind, parallel-
group, placebo-controlled, multicenter clinical study 
(Dowson et al 2002) that compared almotriptan, 12.5 mg 
and 25 mg, with sumatriptan 100 mg, a very low rate of AEs 
was found for both the study drugs. In particular, almotriptan 
12.5 mg showed a signiﬁ  cantly better AE proﬁ  le than both 
placebo (almotriptan = 8.7%, placebo = 6.1%; p = 0.493) 
and sumatriptan (almotriptan 12.5 mg = 8.7%, sumatriptan 
100 mg = 22.2%; p   0.001). Conversely, no signiﬁ  cant 
difference was found between the AE proﬁ  le of almotriptan 
25 mg and sumatriptan 100 mg.
In another tolerability study, almotriptan 12.5 mg 
was compared with sumatriptan 50 mg (Spierings et al 
2001). Both drugs showed a good tolerability proﬁ  le and 
no serious AEs were reported. The difference in term of 
treatment-emergent AEs and treatment-related AEs was 
favorable to almotriptan with an almost signiﬁ  cant difference 
(p = 0.06) in the treatment-emergent AEs (15.2% almotrip-
tan, 19.4% sumatriptan) and with high level of signiﬁ  cance 
(p = 0.001) in the treatment-related AEs (9.1% almotriptan, 
15.5% sumatriptan) with respect to sumatriptan, including 
the incidence of chest pain (0.3 vs 2.2%, p = 0.004).
It is worthy of note that, of all the triptans, almotriptan 
has been reported to show the lowest incidence of cen-
tral nervous system (CNS)-related side-effects (Dodick 
and Martin 2004). The most frequent CNS-related side-
effects of the triptans are dizziness and somnolence, and 
a meta-analysis of 53 studies has shown that almotriptan 
12.5 mg (–1.5%) and naratriptan 2.5 mg (1.9%) express 
them with the lowest incidence (Ferrari et al 2001). Pos-
sible explanations could lie in the very low lipophilicity of 
these compounds and their absence of active metabolites 
(Dodick and Martin 2004). In a double-blind, randomized 
clinical trial (Colman et al 2001) evaluating more than 
one thousand, one hundred migraine patients treated with 
almotriptan 12.5 mg or sumatriptan 50 mg, the side-effect 
proﬁ  le was found to be signiﬁ  cantly better (p = 0.016) in 
the almotriptan-treated patients than in the sumatritptan-
treated ones.
Almotriptan and the other triptans
Although all the second-generation triptans have been 
compared head-to-head with sumatriptan, few studies have 
compared the second-generation triptans with each other, and 
most comparative conclusions regarding these new agents 
have been derived from meta-analyses of pooled data. One 
large meta-analysis of 53 clinical trials of oral triptans used 
for the acute treatment of migraine, including more than 
24,000 patients, showed that almotriptan 12.5 mg, eletriptan 
80 mg and rizatriptan 10 mg had the highest likelihood of 
consistent success, in particular concerning the SPF rates 
(Ferrari et al 2001). In direct head-to-head trials of almo-
triptan versus sumatriptan, almotriptan was not superior to 
sumatriptan on any efﬁ  cacy end point (Pascual et al 2000; 
Spierings et al 2001).
More recently, a large, multinational, randomized, 
double-blind trial including 1298 migraineurs (Goadsby 
et al 2007) has compared almotriptan 12.5 mg and zolmi-
triptan 2.5 mg in the treatment of acute migraine. This trial 
is also the ﬁ  rst study to assess the triptans prospectively 
using SNAE as the primary endpoint, while the secondary 
endpoints were 2-h pain relief, 2-h pain free, SPF, head-
ache recurrence, and use of rescue medication. The results Neuropsychiatric Disease and Treatment 2007:3(6) 807
Almotriptan in the treatment of migraine
showed that there were no differences between almotriptan 
and zolmitriptan, either in the primary endpoint (SNAE, 
almotriptan 29.2% vs zolmitriptan 31.8%) or in any of the 
secondary endpoints. However, compared with zolmitriptan, 
almotriptan was associated with signiﬁ  cantly lower rates 
of triptan-associated AEs and triptan-associated CNS AEs. 
Fatigue (2.1% and 4.0% in the almotriptan 12.5 mg and 
zolmitriptan 2.5-mg groups respectively) and dizziness 
(1.3% and 2.5%) were among the most common treatment-
associated AEs.
In a retrospective analysis (Allais et al 2006) of a trial 
comparing almotriptan 12.5 mg and zolmitriptan 2.5 mg 
and involving more than 1000 migraineurs, the efﬁ  cacy 
and tolerability proﬁ  le of these two triptans was compared 
in a selected sub-population of 255 patients with menstrual 
migraine. The efﬁ  cacy endpoints considered were pain 
relief at 0.5, 1, 1.5 and 2 h; pain-free at 0.5, 1, 1.5 and 2 h; 
SPF; use of rescue medication within 24 h of drug intake; 
recurrence within 24 h of treatment; and level of functional 
impairment before drug intake and after 0.5, 1, 1.5 and 2 h. 
Almotriptan and zolmitriptan showed similar efﬁ  cacy and 
tolerability when used to treat menstrual migraine attacks: 2 h 
after dosing, 67.9% of almotriptan-treated and 68.6% of zol-
mitriptan-treated patients had obtained pain relief, whereas 
44.9% and 41.2%, respectively, were pain-free. Recurrence 
rates 2–24 h after dosing were 32.8% for almotriptan and 
34.7% for zolmitriptan.
Treatment of acute migraine
in adolescents
Despite the high prevalence of migraine in adolescents (about 
10%), and its considerable impact on their quality of life 
(Hamalainen 2006), data on the efﬁ  cacy of symptomatic treat-
ment of migraine attacks in adolescent patients are too few allow 
recommendation of the triptans in this age group. In the few 
studies that have been published on the use of triptans in pedi-
atric patients, nasal sumatriptan and rizatriptan have emerged 
as effective and safe in children and adolescents respectively 
(Hershey et al 2001; Winner et al 2002). The efﬁ  cacy and 
safety of almotriptan has recently (Charles et al 2006) been 
investigated in a small group of 15 migraineurs, aged from 11 
to 17 years. In all 15 patients, almotriptan (6.25 and 12.5 mg) 
brought rapid onset of pain relief. There was no re-dosing 
in  24 h in any patient. All the patients were able to continue 
their normal daily activity during the treatment. No serious AEs 
were reported; one patient described transient mild stiffness. 
However, a large population study is necessary to conﬁ  rm this 
interesting proﬁ  le of efﬁ  cacy and tolerability of almotriptan.
Conclusions
According to the American Academy of Neurology guide-
lines, the triptans are, on the basis of the significantly 
better efﬁ  cacy demonstrated in comparative studies, to be 
considered the ﬁ  rst choice for the treatment of moderate-
severe migraine attacks as well as when other treatments fail 
(Silberstein et al 2000).
The results of controlled clinical trials show almotriptan 
to be efﬁ  cacious and well tolerated when used to treat acute 
migraine attacks. Results from comparative studies and a 
meta-analysis of 53 randomized, placebo-controlled studies 
conﬁ  rm that almotriptan 12.5 mg demonstrates comparable 
efﬁ  cacy with sumatriptan 50 and 100 mg. It is worth noting 
that (at the dose of 12.5 mg) almotriptan emerged as the 
triptan with the lowest AE rate coupled with the highest 
SPF rate, and thus with the best SNAE rate. Its rapid onset 
of effect (in terms of pain relief and pain-free rate), complete 
the characteristics of this triptan.
This very favorable proﬁ  le makes almotriptan 12.5 mg 
one of the ﬁ  rst therapeutic options in the treatment of acute 
migraine attacks, and particularly suitable for early treatment 
of the attack.
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